Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$0.80
+0.7%
$0.83
$0.66
$2.43
$93.91M0.862.67 million shs679,404 shs
Curis, Inc. stock logo
CRIS
Curis
$1.84
+5.1%
$2.19
$1.02
$8.29
$18.94M3.679,828 shs131,473 shs
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.61
+0.6%
$1.18
$1.78
$40.66
$48.54M1.4620,672 shs138,723 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$10.79
-0.6%
$11.30
$5.78
$22.00
$1.36B2.39277,165 shs208,906 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$33.24
-0.1%
$33.32
$27.66
$121.06
$4.29B1.191.47 million shs474,884 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
0.00%+7.79%+0.50%+2.46%-42.37%
Curis, Inc. stock logo
CRIS
Curis
0.00%-15.21%-22.03%+49.59%-70.56%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
+0.63%+7.33%+53.33%+29.84%+129.77%
Mesoblast Limited stock logo
MESO
Mesoblast
0.00%-1.19%-5.85%+2.08%+58.56%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%+2.01%-1.79%+5.17%-56.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
3.6332 of 5 stars
3.31.00.04.50.02.50.6
Curis, Inc. stock logo
CRIS
Curis
2.887 of 5 stars
3.55.00.00.02.30.00.6
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
2.3792 of 5 stars
3.51.00.00.03.70.80.6
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.7969 of 5 stars
3.61.00.00.02.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
2.67
Moderate Buy$4.68484.69% Upside
Curis, Inc. stock logo
CRIS
Curis
3.00
Buy$17.00823.91% Upside
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
3.00
Buy$18.0066.82% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50310.71% Upside

Current Analyst Ratings Breakdown

Latest CRTX, CRIS, CHRS, PCVX, and MESO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
4/29/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/24/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.05
4/22/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
4/8/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$266.96M0.35$0.29 per share2.78($1.14) per share-0.70
Curis, Inc. stock logo
CRIS
Curis
$10.91M1.76N/AN/A($0.71) per share-2.59
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Mesoblast Limited stock logo
MESO
Mesoblast
$5.90M233.69N/AN/A$4.21 per share2.56
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$28.51M-$1.13N/AN/AN/A-66.30%N/A-26.51%8/6/2025 (Estimated)
Curis, Inc. stock logo
CRIS
Curis
-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%7/30/2025 (Estimated)
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)

Latest CRTX, CRIS, CHRS, PCVX, and MESO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/12/2025Q1 2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.31-$0.35-$0.04-$0.49$59.79 million$7.60 million
5/6/2025Q1 2025
Curis, Inc. stock logo
CRIS
Curis
-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/AN/AN/AN/AN/A
Curis, Inc. stock logo
CRIS
Curis
N/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/A
1.22
1.20
Curis, Inc. stock logo
CRIS
Curis
N/A
1.23
1.23
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Mesoblast Limited stock logo
MESO
Mesoblast
0.22
0.96
0.63
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70

Institutional Ownership

CompanyInstitutional Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
72.82%
Curis, Inc. stock logo
CRIS
Curis
29.97%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
8.08%
Curis, Inc. stock logo
CRIS
Curis
5.45%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
330115.93 million106.57 millionOptionable
Curis, Inc. stock logo
CRIS
Curis
6010.46 million9.89 millionNo Data
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Mesoblast Limited stock logo
MESO
Mesoblast
80127.78 million103.76 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable

Recent News About These Companies

Vaxcyte: Sentiment Is Pushing The Shares Down
Vaxcyte appoints new independent director

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Coherus Oncology stock logo

Coherus Oncology NASDAQ:CHRS

$0.80 +0.01 (+0.74%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$0.78 -0.03 (-3.12%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Curis stock logo

Curis NASDAQ:CRIS

$1.84 +0.09 (+5.14%)
Closing price 07/3/2025 01:59 PM Eastern
Extended Trading
$1.78 -0.06 (-2.99%)
As of 07/3/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.61 +0.01 (+0.63%)
As of 07/3/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$10.79 -0.07 (-0.64%)
Closing price 07/3/2025 03:26 PM Eastern
Extended Trading
$10.79 0.00 (0.00%)
As of 07/3/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$33.24 -0.04 (-0.11%)
As of 07/3/2025 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.